Literature DB >> 12596222

Sex steroids, ANGELS and osteoporosis.

Jonathan G Moggs1, Damian G Deavall, George Orphanides.   

Abstract

Osteoporosis is characterized by reduced bone density and strength. Bone mass peaks between age 30 and 40 and then declines. This can be accelerated by factors including menopause and insufficient dietary calcium. Hormone replacement therapy (HRT) is currently the standard treatment for osteoporosis. However, growing concern over potential side effects of HRT has driven a search for alternative therapies. A recent report 1 reveals a potential alternative to HRT: a gender-neutral synthetic steroid that increases bone mass and strength without affecting reproductive organs. This compound acts via a novel extranuclear sex steroid receptor signaling mechanism that has important implications for nuclear receptor biology and human health. Copyright 2003 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12596222     DOI: 10.1002/bies.10249

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  6 in total

1.  Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor.

Authors:  Sara H Windahl; René Galien; Riccardo Chiusaroli; Philippe Clément-Lacroix; Frederic Morvan; Liên Lepescheux; François Nique; William C Horne; Michèle Resche-Rigon; Roland Baron
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

2.  Induction of osteoblast differentiation by selective activation of kinase-mediated actions of the estrogen receptor.

Authors:  Stavroula Kousteni; Maria Almeida; Li Han; Teresita Bellido; Robert L Jilka; Stavros C Manolagas
Journal:  Mol Cell Biol       Date:  2006-12-11       Impact factor: 4.272

Review 3.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

4.  Phenotypic anchoring of gene expression changes during estrogen-induced uterine growth.

Authors:  Jonathan G Moggs; Helen Tinwell; Tracey Spurway; Hur-Song Chang; Ian Pate; Fei Ling Lim; David J Moore; Anthony Soames; Ruth Stuckey; Richard Currie; Tong Zhu; Ian Kimber; John Ashby; George Orphanides
Journal:  Environ Health Perspect       Date:  2004-11       Impact factor: 9.031

5.  Genetic studies of bone diseases: evidence for involvement of DNA damage response proteins in bone remodeling.

Authors:  Xueying Wang; Baojie Li
Journal:  Int J Biomed Sci       Date:  2007-12

Review 6.  P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development.

Authors:  T Velletri; N Xie; Y Wang; Y Huang; Q Yang; X Chen; Q Chen; P Shou; Y Gan; G Cao; G Melino; Y Shi
Journal:  Cell Death Dis       Date:  2016-01-21       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.